AstraZeneca's Breast Cancer Drug Camizestrant Fails Main Goal in Late-Stage Trial Written By sheeba farhat12 Sept 2026 6:30 PM ISTBengaluru: AstraZeneca's breast cancer pill failed to meet the main goal of improving progression-free survival in a late-stage trial, the company...
AstraZeneca Gets CDSCO Nod to Market Enhertu for New Breast Cancer Indication Written By Parthika Patel8 Aug 2026 9:00 PM ISTBengaluru: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization (CDSCO), Directorate General...
USFDA Approves Celcuity's First Cancer Drug Revtorpyk for Advanced Breast Cancer Written By sheeba farhat15 July 2026 9:45 PM ISTBengaluru: The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the regulator said on Tuesday, making it the company's...
Eli Lilly Hands China Rights for Breast Cancer Drug Verzenio to Innovent Biologics Written By sheeba farhat1 July 2026 10:30 AM ISTShanghai: Eli Lilly has transferred the mainland China commercialization rights for its breast cancer drug Verzenios to Innovent Biologics, the...
AstraZeneca Gets EMA Panel Nod for Camizestrant Breast Cancer Pill After USFDA Setback Written By sheeba farhat24 May 2026 10:30 AM ISTLondon: A European Medicines Agency committee on Friday backed approval for AstraZeneca's experimental breast cancer pill, camizestrant, differing...
Abemaciclib's New Overall Survival Data in Early Breast Cancer: Findings from MonarchE trial Written By Medical Dialogues Team8 Jan 2026 12:00 PM ISTIn this short video, Prof Stephen Johnston, Consultant Medical Oncologist, Royal Marsden Hospital and Institute of Cancer Research, London, ...
Abemaciclib Delivers New Overall Survival Data in Early Breast Cancer Patients Written By Medical Dialogues Team7 Jan 2026 10:45 AM ISTIn this short video, Prof Stephen Johnston, Consultant Medical Oncologist, Royal Marsden Hospital and Institute of Cancer Research, London, ...
2 Years of Treatment, 7 Years of Benefits: Abemaciclib Delivers New Overall Survival Data in Breast Cancer Patients Written By Medical Dialogues Team26 Dec 2025 11:45 AM ISTIn this short video, Dr Nitesh Rohtagi, Principal Director, Department of Medical Oncology, Fortis Cancer Institute, Delhi and Gurugram, discusses...
ESMO 2025 Update: Effect of Abemaciclib added to standard Endocrine Therapy in High-Risk Early Breast Cancer Written By Medical Dialogues Team23 Dec 2025 11:30 AM ISTAdjuvant abemaciclib combined with endocrine therapy (ET) has demonstrated a statistically significant and clinically meaningful improvement in...
Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer Written By Dr. Nandita Mohan22 Sept 2025 5:47 PM ISTAlkem aims to expand access to treatment with its affordable pertuzumab biosimilar that meets global standards and is backed by trusted science ...
Real-World Case: Managing Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Akhil Kapoor Written By Dr Akhil Kapoor21 Aug 2025 12:30 PM ISTIn this video, Dr. Akhil Kapoor, Medical Oncologist at Tata Memorial Centre, Varanasi, Uttar Pradesh, discusses a real-world case study of...
CDSCO Panel Clears AstraZeneca's Datopotamab for Breast Cancer, Seeks Phase IV Trial Parthika Patel20 July 2025 1:03 AM ISTNew Delhi: The Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has granted...
